Mirabegron and Tysabri drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Mirabegron (mirabegron) and Tysabri (natalizumab). Common drug interactions include headache among females and anxiety among males.

The phase IV clinical study analyzes what interactions people have when they take Mirabegron and Tysabri. It is created by eHealthMe based on reports of 31 people who take the same drugs from the FDA, and is updated regularly.

What is Mirabegron?

Mirabegron has active ingredients of mirabegron. It is often used in urge incontinence. eHealthMe is studying from 5,414 Mirabegron users. Check the latest studies of Mirabegron.

What is Tysabri?

Tysabri has active ingredients of natalizumab. It is often used in multiple sclerosis. eHealthMe is studying from 221,369 Tysabri users. Check the latest studies of Tysabri.



On Jul, 14, 2026

31 people who take Mirabegron and Tysabri together, and have interactions are studied.

Mirabegron and Tysabri drug interactions.

What are the common drug interactions of Mirabegron and Tysabri, by gender? *:

female:

  1. Headache (pain in head)
  2. Hypoacusis (loss of hearing)
  3. Immune system disorder
  4. Lower respiratory tract infection viral
  5. Sepsis (a severe blood infection that can lead to organ failure and death)
  6. Hemiplegia (paralysis of one side of the body)
  7. Asthenia (weakness)
  8. Depression
  9. Stress
  10. Urticaria (rash of round, red welts on the skin that itch intensely)

male:

  1. Anxiety
  2. Pollakiuria (abnormally frequent passage of relatively small quantities or urine)
  3. Asthenia (weakness)
  4. Balance disorder
  5. Bladder spasm
  6. Bradykinesia (decreased bodily movement. it is associated with basal ganglia diseases)
  7. Bruxism (habitual grinding of the teeth, typically during sleep)
  8. Central nervous system lesion (an abnormality in tissue of brain or spinal cord)
  9. Chorea (abnormal involuntary movement disorder)
  10. Constipation

What are the common drug interactions of Mirabegron and Tysabri, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Fatigue (feeling of tiredness)
  2. Stress

30-39:

  1. Cystitis (inflammation of the wall of the bladder)
  2. Alopecia (absence of hair from areas of the body)
  3. Anaemia (lack of blood)
  4. Contusion (a type of hematoma of tissue in which capillaries)
  5. Cystitis interstitial (unknown cause characterized by bladder pain)
  6. Dental caries
  7. Gastrointestinal inflammation (inflammation of stomach and intestine)
  8. Gastrointestinal pain
  9. Genital infection fungal
  10. Herpes zoster

40-49:

  1. Lung adenocarcinoma (a form of non-small cell lung cancer)
  2. Hypersensitivity pneumonitis
  3. Interstitial lung disease

50-59:

  1. Obesity (having too much body fat)
  2. Ocular hyperaemia (an abnormally large amount of blood in eye)
  3. Oedema peripheral (superficial swelling)
  4. Pain in extremity
  5. Parkinson's disease
  6. Peripheral coldness
  7. Photosensitivity reaction
  8. Pollakiuria (abnormally frequent passage of relatively small quantities or urine)
  9. Prostatic disorder
  10. Prostatitis (inflammation of the prostate gland)

60+:

  1. Fatigue (feeling of tiredness)
  2. Asthenia (weakness)
  3. Arthralgia (joint pain)
  4. Back pain
  5. Balance disorder
  6. Bladder dysfunction
  7. Blood pressure immeasurable
  8. Burning sensation
  9. Chills (felling of cold)
  10. Depression

What are the existing conditions these people have? *

  1. Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 8 people, 25.81%
  2. Gait Disturbance: 8 people, 25.81%
  3. Wheezing (a high-pitched whistling sound made while you breath): 2 people, 6.45%
  4. Urination - Excessive At Night: 2 people, 6.45%
  5. Trigeminal Neuralgia (a painful condition of the nerve responsible for most facial sensation): 2 people, 6.45%
  6. Neuralgia (pain in one or more nerves): 2 people, 6.45%
  7. Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 2 people, 6.45%
  8. Muscle Spasms (muscle contraction): 2 people, 6.45%
  9. Insomnia (sleeplessness): 2 people, 6.45%
  10. Fatigue (feeling of tiredness): 2 people, 6.45%

* Approximation only. Some reports may have incomplete information.

Do you take Mirabegron and Tysabri?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Mirabegron and Tysabri:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Mirabegron:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Tysabri:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Mirabegron and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tysabri and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on mirabegron and natalizumab (the active ingredients of Mirabegron and Tysabri, respectively), and Mirabegron and Tysabri (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: